Kornimate/medical-research-clean huggingface dataset:
cocaine, lidocaine/xylometazoline and saline for nasal analgesia

Conditions: Analgesia

Summary: when performed by trained personnel nasotracheal intubation is a safe and effective technique for attaining a secure airway in preparation for surgery of the head and neck. the procedure can be deemed necessary due to the nature of the surgical procedure or considerations in regard to the patient's comorbidities. for a certain group of patients with expected difficult airways, the procedure is done whilst they are awake and aided by fiberoptics. for these awake patients, extra precautions must be taken to ensure the procedure is conducted with minimal pain and discomfort. the pain and discomfort arises from the mechanical manipulation of the nasal mucosa and can be alleviated in part by means of topical analgesia as well as through decongestion, providing more space within the nasal cavity. for these purposes, several drugs in varying combinations and dosages are used, but no single drug choice is universally recommended. cocaine is one of these appropriate drugs. it is a magistral formula used especially due to its unique combination of both vasoconstrictive and analgesic properties. concerns have though been raised regarding cocaine's potential toxicity and alternative medications are continuously sought after. a combination of lidocaine and xylometazoline can also be used for preparation of the nose prior to awake nasal fiberoptic intubation. lidocaine contributes with its analgesic effect whilst xylometazoline functions as the vasoconstrictor. the investigators wish to compare the analgesic effects of cocaine and lidocaine/phenylephrine to each other and saline when subjectively scored on a visual analogue scale of 0-100 mm immediately after simulated awake nasal intubation on healthy volunteers.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * proficient in spoken and written danish * healthy volunteers (no active diagnoses) * negative hcg (human chorionic gonadotropin) urine stix for women of childbearing potential exclusion criteria: * known nasal malformation * known coagulopathy * current antithrombotic treatment * self-reported epistaxis occurring more than once a month * symptoms of a common cold within the past week * hypersensitivity to local anaesthetics of amide type or any of the excipients * hypertension * narrow-angle glaucoma
serum immunoglobulin (g) as a marker of diabetic nephropathy

Conditions: Diabetic Nephropathies

Summary: diabetes mellitus is a chronic disease that affects 366 million people worldwide ( 6.4 % of the adult population ) and is expected to rise to 522 million by 2030 . diabetic nephropathy occurs in approximately one - third of all people with diabetes and is the leading cause of renal failure in developed and developing countries diabetic nephropathy is a severe complication occurring in diabetic patients and it is associated with an increased risk of all- cause mortality , cardiovascular disease and progression to end stage renal disease , requiring costly renal replacement therapy in the form of dialysis or transplantation


Eligibility criteria:
inclusion criteria: * type 2 diabetic patients exclusion criteria: * patients with diabetes type 1 , * pregnant and lactating females , * patients with any congenital disease , infection , smokers , alcoholics , and drug abusers .
a single and multiple ascending dose study of ck-3773274 in healthy adult subjects

Conditions: Symptomatic Obstructive Hypertrophic Cardiomyopathy; Healthy Subjects

Summary: the purposes of this study are to: 1. learn about the safety of ck-3773274 after a single dose and multiple doses in healthy subjects. 2. learn how healthy subjects tolerate ck-3773274 after a single dose and multiple doses. 3. find out how much ck-3773274 is in the blood after a single dose and multiple doses. 4. determine the effect of doses of ck-3773274 on the pumping function of the heart. 5. evaluate the effect of cytochrome genetic variants on how the body metabolizes ck-3773274. 6. evaluate the effect of a meal on how much ck-3773274 is in the blood in healthy adult subjects. 7. evaluate whether the amount of ck-3773274 in the blood is the similar for both the tablet and granules in capsule forms of the drug.


Eligibility criteria:
inclusion criteria: 1. males and females (of non-childbearing potential) between 18 and 55 years of age, inclusive 2. body weight \> 55.0 kg and body mass index within 18.0 to 32.0 kg/m2, inclusive 3. normal cardiac structure and function, or if abnormalities are present, they are deemed not clinically significant 4. normal to high left ventricular ejection fraction. 5. normal electrocardiogram (ecg) or, if abnormalities are present, they are deemed not clinically significant 6. clinical laboratory findings within normal range 7. negative hepatitis panel (including hepatitis b surface antigen and hepatitis c antibody), and negative human immunodeficiency virus antibody screens 8. willing and able to refrain from strenuous exercise (eg, activity which could be expected to cause muscle soreness) 9. for arms 5 and 6 only: subject is a cyp2d6 poor metabolizer exclusion criteria: 1. history of any significant illness or disorder 2. history of stomach or intestinal surgery or resection (appendectomy, hernia repair, and/or cholecystectomy will be allowed) 3. a clinically significant illness within 4 weeks of check-in 4. inability to swallow capsules or tablets 5. history of or current substance abuse (drug or alcohol), known drug or alcohol dependence within the last 2 years prior to screening, or positive test for drugs of abuse during the screening period 6. use of any tobacco-containing or nicotine-containing products within 3 months prior to check-in 7. participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days prior to check-in 8. any blood donation within 60 days of dosing, plasma donation within 30 days of dosing, or receipt of blood products within 2 months prior to check-in

Keywords: ck-3773274 ck-274 obstructive hypertrophic cardiomyopathy ohcm aficamten
toripalimab combined with axitinib as neoadjuvant therapy in patients with non-metastatic locally advanced nonmetastatic clear cell renal cell carcinoma

Conditions: Neoadjuvant Therapy of Non-metastatic Locally Advanced Renal Cell Carcinoma

Summary: this study is design to prospectively investigate the safety and efficacy of toripalimab combined with axitinib in downsizing tumors in patients with nonmetastatic biopsy-proven clear cell renal cell carcinoma. toripalimab is new antibody that may help activate the immune system by blocking the function of an inhibitory molecule, programmed cell death-1 (pd-1). this is a single-institution, single-arm phase 2 clinical trial.

this study is design to prospectively investigate the safety and efficacy of toripalimab combined with axitinib in downsizing tumors in patients with nonmetastatic biopsy-proven clear cell renal cell carcinoma. toripalimab is new antibody that may help activate the immune system by blocking the function of an inhibitory molecule, programmed cell death-1 (pd-1). this is a single-institution, single-arm phase 2 clinical trial. patients will receive axitinib 5 mg bid combined with toripalimab 3mg/kg q3w for up to 12 wk. patients then will receive partial or radical nephrectomy after neoadjuvant therapy.

Eligibility criteria:
inclusion criteria: * non-metastatic biopsy-proven clear cell renal cell carcinoma (t2-t3n0-1m0) * schedule to undergo either partial or radical nephrectomy as part of treatment plan * ecog performance status of 0 or 1 * adequate organ and marrow function defined by study-specified laboratory tests * agree to comply with scheduled visits, treatment plans, lab tests and other study procedures * do not have any other cancers in the 5 yr preceding diagnosis of their renal cancer exclusion criteria: * patients who have received other systems for anti-tumor treatment * patients who have previously received targeted or immunotherapy * need for urgent or emergent nephrectomy to relieve symptoms * current use of immunosuppressive agents * pregnant or breastfeeding women * history of autoimmune disease or syndrome

Keywords: neoadjuvant therapy toripalimab axitinib nephrectomy partial nephrectomy
antireflux ablation of the cardia mucosa vs placebo for the treatment of gastroesophageal reflux disease

Conditions: Gastroesophageal Reflux Disease

Summary: the arma technique improves gord-related quality of life with a low proportion of adverse effects.

gastroesophageal reflux disease (gerd) is defined as the presence of symptoms or complications secondary to the passage of gastric contents into the esophagus, oral cavity or structures of the airway. the prevalence worldwide is between 8-33%. the clinical practice guidelines of the american college of gastroenterology establish that first-line treatment, in the absence of alarm symptoms, should be carried out empirically. this treatment consists of hygienic-dietary measures and the use of proton pump inhibitors (ppis) for 8-12 weeks. despite the proven effectiveness of ppis, there is 10-40% of patients who do not respond adequately to this treatment. all this has motivated the appearance of endoscopic and surgical techniques that offer an alternative to medical treatment. among them is the technique of antireflux ablation of the cardiac mucosa (arma) in which the resection of the mucosa is replaced by an ablation with electrocoagulation current or by argon gas fulguration.

Eligibility criteria:
inclusion criteria: 1. age over 18 years. 2. gerd symptoms lasting more than 6 months, not necessarily consecutive. they should at least have a typical gerd symptom (heartburn or regurgitation). 3. total acid exposure time\> 6% in ph measurement study without ppi treatment. 4. patients who do not want to take ppis or with chronic consumption, defined as ppi consumption of more than 6 months (consecutive or not) in the last 2 years. 5. response to ppi treatment, defined as an increase of\> 10 points on the gerd-hrql questionnaire 15 days after discontinuation of the ppi. 6. written informed consent to participate in the study. exclusion criteria: 1. patients with sliding hiatal hernia\> 2 cm. 2. presence of only atypical gerd symptoms. 3. age\> 75 years. 4. grade d peptic esophagitis. 5. body mass index\> 35 40 kg / m2. 6. liver cirrhosis. 7. pregnancy. 8. incomplete relaxation of the les in mar (pir\> 15 mmhg). 9. absent peristalsis, defined as 100% failed waves with dci \<100 mmhg \* cm \* s in mar. 10. esophagogastric surgery or previous endoscopic antireflux technique. 11. barrett's esophagus with dysplasia. 12. oncological disease. 13. esophageal strictures or ulcers. 14. severe cardiopulmonary comorbidity (asa functional class iv-v). 15. previously known coagulopathy. 16. severe psychiatric disorder 17. refusal to participate in the study.

Keywords: endoscopy argon gas antireflux ablation of the cardiac mucosa (arma)
single-center study of gustation in idiopathic parkinson's disease and lewy body disease using gustatory evoked potential analysis

Conditions: Idiopathic Parkinson's Disease and Lewy Body Disease

Summary: the aim of the pi-peg study is to explore the taste functions of the following 3 groups of participants: * healthy volunteers * patients with early parkinson's disease * patients with incipient lewy body disease. to this end, the results obtained from taste evoked potentials in each of the 3 groups of participants will be compared with each other and with different nutritional, motor and cognitive data. this study could reveal a difference in cortical processing of gustatory sensory information between patients who have had idiopathic parkinson's disease progressing for 3 years or less, and patients who have had lewy body disease progressing for 3 years or less. indeed, a modification of taste evoked potentials (in terms of latencies) proportional to the degree of cerebral degeneration could be observed.


Eligibility criteria:
inclusion criteria: healthy volunteers: * person who has given written consent * adult * enrolled in the national register of healthy volunteers * fasting \> 2 hours before peg measurement * body mass index (bmi) \< 30 kg/m². * no cognitive complaints and normal neurological assessment patients with idiopathic parkinson's disease: * person who has given written consent * adult * fasting \> 2 hours before peg measurement * body mass index (bmi) \< 30 kg/m². * diagnostic criteria for established or probable ipd patients with lewy body disease: * person who has given written consent * adult * fasting \> 2 hours prior to peg measurement * body mass index (bmi) \< 30 kg/m². * diagnostic criteria for probable or possible lbd exclusion criteria: * non-affiliated to national health insurance * person under legal protection (curatorship, guardianship) * person subject to a court order * pregnant, parturient or breast-feeding women * major unable to give consent * mmse score \< 15 and/or moca \< 10 * known infection with covid-19 in the 6 months prior to inclusion * active smoker (\> 4 cigarettes per day on a regular basis) * subject with pacemaker (contraindication for bioelectrical impedancemetry) * diabetic (type 1 or type 2) * taking medication (in progress at the time of the study) that interferes with gustation
efficacy of l-ornithine l-aspartate in acute hepatic encephalopathy.

Conditions: Hepatic Encephalopathy

Summary: hepatic encephalopathy is caused by the effects on the brain of substances that under normal circumstances are efficiently metabolized in the liver. the hyperammonemia is the main factor responsible for the development of hepatic encephalopathy. in patients with cirrhosis, the reduction in hepatocellular function and generation of portosystemic shunts contribute to increase serum ammonium. the current therapeutic approaches, are aimed at reducing blood ammonium levels. administration of the non-absorbable disaccharides, have become standard treatment of hepatic encephalopathy.there are no adequate clinical trials comparing the efficacy of l-ornithine-l-aspartate (lola) infusion against lactose enemas in the treatment of acute hepatic encephalopathy.

the main impact of hepatic encephalopathy in patients with cirrhosis is not related to costs, but its association with decreased survival and quality of life and should therefore clearly established the effectiveness of therapeutic interventions used in this disorder. at the end of the nineteenth century to the ammonium was identified as the main agent responsible for the development of the syndrome of hepatic encephalopathy. since then, reduced nitrogen compounds from the intestine are considered the main therapeutic measure. on this conceptual base, nonabsorbable disaccharides are the first line therapy in hepatic encephalopathy. current knowledge indicates that other organs such as muscle, brain and kidney are involved in the generation of ammonium, which has set the pace for the development of new treatments, able to act systemically in metabolism and elimination of ammonia . l-ornithine l-aspartate (lola) lowers ammonium concentrations in animal and humans models with hyperammonemia. there are no adequate clinical trials comparing the efficacy of lola infusion against lactose enemas in the treatment of acute hepatic encephalopathy.

Eligibility criteria:
inclusion criteria: * patients with cirrhosis of any etiology, diagnosed by ultrasound,clinical and / or histologic criteria * patients over 18 years and under 75 * patients with hepatic encephalopathy grade 3-4 according to the criteria of west haven * patients with hyperammonemia \>10 µmol/l exclusion criteria: * evidence of neurological or psychiatric illness * use of drugs affecting the central nervous system * withdrawal syndrome * anorectal disease that interferes with the administration of enemas

Keywords: encephalopathy cirrhosis
left atrial mechanical function improvement after atrial fibrillation catheter ablation

Conditions: Atrial Fibrillation

Summary: the objective of the study was to estimate the efficacy of telmisartan and amlodipine combination on the restoration of left atrial mechanical function after atrial fibrillation catheter ablation.

64 candidates to atrial fibrillation ablation were included in the study. patients were randomly assigned to telmisartan/amlodipine combination in dose 80/5 mg (group i, n=34) or placebo (group ii, n=30) taking daily for up to one week. echocardiography was performed before the procedure, immediately after it, and after a week of therapy. the six-minute walk test and sf-36 questionnaire results were evaluated a day before the procedure and after a week of the therapy. the left ventricular end-diastolic pressure was invasively measured after transseptal puncture and before left atrial sheath removal.

Eligibility criteria:
inclusion criteria: * symptomatic (iii-iv class by european heart rhythm association scale) paroxysmal atrial fibrillation; * ineffective therapy by at least one of the class i or iii antiarrhythmic drugs; * left atrial diameter 5 cm or less; * estimated catheter radiofrequency pulmonary vein antrum isolation; * signed informed consent. exclusion criteria: * intolerance/allergy or contraindications to telmisartan, amlodipine, warfarin or enoxaparin; * left atrial thrombosis; * age greater than 75 years; * severe (e.g. decompensation of vital functions) or acute (e.g. pneumonia) somatic conditions; * malignant growth in the hematogenic dissemination stage.

Keywords: atrial fibrillation catheter ablation left atrium mechanical function contractility
a preliminary study on the detection of plasma markers in early diagnosis for lung cancer

Conditions: Lung Cancer

Summary: lung cancer is the most common cancer with the highest morbidity and mortality in the world. stagement is closely related to the 5 years of survival rate of patients. the postoperative 5-year survival rate is above 90% for stage ⅰa lung cancer patients, while the 5-year survival rate of stage iv lung cancer patients is less than 5%. therefore, early screening and diagnosis for lung cancer is a key method to reduce lung cancer mortality and prolong survival for patients. at present, low-dose computed tomography (ldct) is the most effective method for early detection of lung cancer. in addition to imaging examination, plasma tumor markers detection is also a common clinical detection method for tumor screening and postoperative monitoring. liquid biopsy is a non-invasive or minimally invasive method for testing blood or other liquid samples to analyze tumor-related markers including nucleic acids and proteins. several studies have explored the detection of hot spot gene mutations, methylation and methylation changes of dna, protein markers and autoantibodies in peripheral blood in lung cancer patients. liquid biopsy has generally become the most popular field for early diagnosis of lung cancer. based above, it is necessary to combine multi-omics methods to improve the detection of early stage lung cancer. in our study, we intend to integrate molecular features obtained through liquid biopsy and clinical data of lung cancer patients, and develop and prospectively validate a machine-learning method which can robustly discriminate early-stage lung cancer patients from controls.


Eligibility criteria:
inclusion criteria: * enrolled patients are newly diagnosed patients * in patients diagnosed as pulmonary nodules by imaging, benign and malignant conditions of the nodules are determined by postoperative pathology after surgical resection * there is clear cancer stage information * in addition to pulmonary nodules, there are no suspicious nodules of other organs * no previous history of malignant tumor exclusion criteria: * patients with a history of malignant tumor * patients with suspectednodules in other parts of the body at the time of diagnosis * patients who have previously received surgery, chemotherapy or radiotherapy for pulmonary lesions * patients with severe blood lipid in peripheral blood extracted which affects subsequent detection
effect of wide pulse pressure on the predictability of stroke volume variation for fluid responsiveness in patients undergoing off-pump coronary artery bypass graft

Conditions: Stroke Volume Variation

Summary: the investigators examined the predictability of stroke volume variation for fluid responsiveness in patients with wide pulse pressure undergoing off-pump coronary artery bypass graft


Eligibility criteria:
inclusion criteria: * 1. age ≥ 20 * 2. elective off-pump coronary artery bypass graft exclusion criteria: * 1. arrhythmia * 2.ef \<40% * 3.valvular heart dz * 4.pul htn * 5.paod * 6.lung dz * 7.nyha iv * 8.esrd
25oh vitamin d overdoses and risk of bronchopulmonary dysplasia or death

Conditions: Bronchopulmonary Dysplasia; Vitamin D Overdose

Summary: several studies have demonstrated that vitamin d deficiency at birth is a risk factor of bronchopulmonary dysplasia. however, in an animal model of bronchopulmonary dysplasia vitamin d overdose has also been associated with an increased mortality and an increased lung injury. such vitamin d overdose has been frequently reported in hospitalized neonates receiving the current supplementation. the hypothesis is that vitamin d overdose is an independent risk factor of bronchopulmonary dysplasia or death among infants born below 31 weeks gestational age excluding infants with vitamin d deficiency. this retrospective cohort study will include all infants born before 31 weeks of gestation (wg), who were hospitalized in a tertiary neonatal intensive care unit (nicu) during at least 10 days, for who at least one 25oh vitamin d determination was performed before 36 wg corrected age and whose parents are not opposed to the study. a descriptive analysis of the cohort depending on the occurrence of vitamin d overdose will be performed. a multivariate analysis will determine if vitamin d overdose is an independent risk factor of bronchopulmonary dysplasia or death among preterm infants, adjusting on the covariates known to be associated with bronchopulmonary dysplasia.


Eligibility criteria:
inclusion criteria: * inclusion criteria \* : * infant born before 31 weeks of gestation. * hospitalized in the nicu during at least 10 days * with at least a 25oh-d determination available before 36 weeks corrected age exclusion criteria: -infant with at least a 25oh-d below 50 nmol/l

Keywords: vitamin d overdoses bronchopulmonary dysplasia preterm infants